October 2026 - Page 2 of 3

Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

FDA Implements Split Payment Framework for FY 2027 OTC Monograph Facility Fees

by Sagarika Sharma | Oct 13, 2026 | FDA

The U.S. Food and Drug Administration (FDA) has established a two-part installment plan for Fiscal Year (FY) 2027 Over-the-Counter (OTC) monograph drug facility user fees. Under this payment schedule, regulated drug establishments must remit their annual facility fees...

First Amendment Milestone: Federal Court Bars California Prop 65 Cancer Warnings for Diethanolamine (DEA)

by Sagarika Sharma | Oct 13, 2026 | California Cosmetic Regulations, U.S. Regulatory

In a landmark decision for cosmetic and personal care manufacturers, a federal court in Sacramento has permanently prohibited the State of California from enforcing Proposition 65 cancer warning mandates for products containing the common surfactant diethanolamine...

FDA issues warning letters to OTC companies over talc testing

by Srishti Chaudhari | Oct 13, 2026 | FDA

In June 2026, the FDA issued nine warning letters to OTC companies over products containing talc, citing concerns about potential asbestos contamination. The letters identified cGMP deficiencies involving ingredient and finished product testing, supplier...

FDA Warning Letter Trends

by Srishti Chaudhari | Oct 13, 2026 | FDA

Recent FDA warning letters to topical OTC manufacturers continue to highlight familiar GMP deficiencies, with supplier oversight and analytical testing emerging as recurring areas of focus. In an August warning letter, the FDA emphasized that companies remain...

Streamlining Post-Market Vigilance: Health Canada Overhauls Guidance on Notifying Foreign Regulatory Actions

by Sagarika Sharma | Oct 13, 2026 | Health Canada Updates

Health Canada has announced a modernized regulatory framework governing how Market Authorization Holders (MAHs) report safety actions and restrictions occurring in international jurisdictions. Officially taking effect on October 1, 2026, the revised guidance...

« Older Entries

Next Entries »

Delsie Braganza

FDA Implements Split Payment Framework for FY 2027 OTC Monograph Facility Fees

First Amendment Milestone: Federal Court Bars California Prop 65 Cancer Warnings for Diethanolamine (DEA)

FDA issues warning letters to OTC companies over talc testing

FDA Warning Letter Trends

Streamlining Post-Market Vigilance: Health Canada Overhauls Guidance on Notifying Foreign Regulatory Actions

Recent Posts

Recent Comments

Archives

Categories